BioMarin Beats Profit Expectation
The Street (Free subscription) | 08/06/2008
But the biopharmaceutical company missed on top-line projections.
- add comment
- send to a friend
- Explore : Biotechnologies, Finance
BioMarin Pharmaceutical
1Vote!
+Vote!
BioMarin Announces Second Quarter 2008 Financial Results
PR News Wire (Free subscription) | 08/05/2008
Second Quarter Profit Driven by Strong Revenue Growth Improved Total Revenue Guidance Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET) NOVATO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Financial Highlights ($ in millions, except per share data) Item Q2 2008 Q2 2007 Comparison Total BioMarin Revenue $64.2 122% increase Naglazyme Net Product Revenue $35.1 67.9% increase ...
- add comment
- send to a friend
- Explore : Biotechnologies, Finance
+Vote!
Children's Memorial Hospital Of Chicago Receives A Grant From BioMarin To Support Adult PKU Outreach
Medical News Today (Free subscription) | 07/23/2008
Children's Memorial Hospital of Chicago has announced that it has received a grant from BioMarin Pharmaceutical Inc. to support its Adult Phenylketonuria (PKU) Outreach Education Project.
- add comment
- send to a friend
- Explore : Biotechnologies, Health
1Vote!
BioMarin and Summit Plc Sign Worldwide Licensing Agreement for Duchenne Muscular Dystrophy Program
Red Orbit (Free subscription) | 07/22/2008
NOVATO, Calif. and OXFORD, England, July 22 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.
+Vote!
Children's Memorial Hospital of Chicago receives a grant from BioMarin to support adult PKU outreach
Eurekalert (Free subscription) | 07/21/2008
( Children's Memorial Hospital ) Children's Memorial received a grant of $102,000 from BioMarin to conduct outreach to PKU patients who are no longer being treated at PKU clinics. Patients are encouraged to seek treatment and education.
- add comment
- send to a friend
- Explore : Biology, Biotechnologies
+Vote!
BioMarin to Host Second Quarter 2008 Financial Results Conference Call ... - PR Newswire
Darmstadt (Free subscription) | 07/15/2008
NOVATO, Calif., July 15 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. NASDAQ: BMRN SWX: BMRN today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host ...
- add comment
- send to a friend
- Explore : Biotechnologies
+Vote!
BioMarin to Present at the Collins Stewart Growth Conference
Red Orbit (Free subscription) | 07/01/2008
NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.
- add comment
- send to a friend
- Explore : Biotechnologies, Health
- BioMarin to Present at the Collins Stewart Growth Conference - PR News Wire
+Vote!
BioMarin, Myriad, and Regeneron Show a Quiet Strength
Seeking Alpha (Free subscription) | 06/26/2008
Zacks.com submits: There seem to be many reasonably priced plays within biotech at the present time, which is a very good thing in a soft market such as the one we have been slogging through. Zacks senior biotech analyst Grant Zeng, CFA was on hand to give us his perspective on the sector recently. Do you expect 2008 will be a strong year for biotech stocks? Complete Story »
- add comment
- send to a friend
- Explore : Biotechnologies, China
+Vote!
BioMarin Selloff Offers a Buy: Analysts
The Street (Free subscription) | 06/24/2008
The stock's selloff Monday was a simple overreaction, say several Wall Street analysts.
- add comment
- send to a friend
- Explore : Biotechnologies, Finance
1Vote!
'Lost' Patients Whack BioMarin Shares
The Street (Free subscription) | 06/24/2008
Investors worry that patients who've lost touch with doctors in a Kuvan study could slow the drug's clinical progress, but the stock's selloff may be overdone.
- add comment
- send to a friend
- Explore : Biotechnologies, Finance
1Vote!
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
PR News Wire (Free subscription) | 06/05/2008
NOVATO, Calif., June 5 /PRNewswire-FirstCall/ - BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced its program for its third enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis IVA (MPS IVA), or Morquio A Syndrome. BioMarin plans to initiate a Phase 1/2 clinical trial in the first quarter of 2009. "With two MPS drugs on the market, we plan to leverage our...
1Vote!
BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
Life Science World (Free subscription) | 05/20/2008
[NEWS] NOVATO, Calif., May 20 /PRNewswire-FirstCall/ — BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 1 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). The study is expected to conclude enrollment in the fourth quarter of 2008. “We are dedicated...
- add comment
- send to a friend
- Explore : Biotechnologies, NASDAQ
- BioMarin Initiates Phase I Phenylketonuria Trial - Red Orbit
- BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU - PR News Wire
1Vote!
Audio: Bull of the Week: BioMarin
Market Watch (Free subscription) | 05/01/2008
Charles Rotblut, senior market analyst for Zacks.com, says that promising enzyme-related therapies being developed for diseases that affect relatively small groups of people have BioMarin positioned for strong performance ahead. In a radio interview, Rotblut made the stock his "Bull of the Week," noting that it basically controls the treatment arenas it is working in, which makes for stability despite...
+Vote!
Sapropterin
Nature (Free subscription) | 02/29/2008
Sapropterin dihydrochloride (Kuvan; BioMarin) is a synthetic form of tetrahydrobiopterin, the natural cofactor for the enzyme phenylalanine hydroxylase (PAH). In December 2007, it became the first drug to be approved by the US FDA for the treatment of phenylketonuria, a genetic disorder that is characterized
- add comment
- send to a friend
- Explore : Artists, Barbara, Biotechnologies, Entertainment, French music, Genetics, Music
